Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 12-Week, Multicenter, Randomized, Parallel-Group Study to Assess the Safety, Tolerability, Pharmacokinetics, Biomarker Effects, Efficacy, and Effect on Microglia Activation, as Measured by Positron Emission Tomography, of AZD3241 in Subjects with Multiple System Atrophy

Next Previous
Trial Profile

A 12-Week, Multicenter, Randomized, Parallel-Group Study to Assess the Safety, Tolerability, Pharmacokinetics, Biomarker Effects, Efficacy, and Effect on Microglia Activation, as Measured by Positron Emission Tomography, of AZD3241 in Subjects with Multiple System Atrophy

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 06 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Verdiperstat (Primary)
  • Indications Multiple system atrophy
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors AstraZeneca

Most Recent Events

  • 31 Jul 2019 Results presented in a Biohaven Pharmaceutical Holding Company media release.
  • 06 Jun 2018 Population pharmacokinetic model for AZD3241 was developed using data from one phase 1 MAD study in healthy subjects (study 02, D0490C00002, NCT00914303), and one phase 2 safety and tolerability study (study 23,D0490C00023, NCT02388295), results published in the Journal of Clinical Pharmacology
  • 24 Mar 2018 Data from one phase I study (NCT00914303) and one phase II study in Multiple System Atrophy (NCT02388295) trial was used to develop PopPK model, results presented at the 119th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top